Legend Biotech shares surged over 41% after first-in-human LB2501 data showed a 100% response rate in B-cell lymphoma patients, validating in vivo CAR-T and intensifying Acquisition speculation in the cell therapy sector.

Key Highlights

  • LEGN shares surged over 41% intraday following first-in-human LB2501 data in B-cell non-Hodgkin lymphoma
  • All six patients at the higher dose level responded; five achieved a complete response
  • In vivo approach eliminates ex vivo Manufacturing, potentially expanding patient access at scale
  • No dose-limiting toxicities, serious adverse events, or ICANS reported across the trial
  • Oppenheimer raises acquisition probability; RBC Capital maintains Outperform with a US$64 price target

A Clinical Readout That Moved Markets

Legend Biotech Corporation (Nasdaq: LEGN) shares climbed more than 41% in intraday trading on June 2, rising from a prior close of US$25.51 to above US$36, after the company released early Phase 1 data for LB2501, its investigational in vivo dual-targeting CAR-T therapy for relapsed or refractory B-cell non-Hodgkin lymphoma.

The readout covered 12 patients across two dose levels as of an April 1 data cutoff. At the higher dose level, all six patients demonstrated an objective response, with five achieving a complete response, representing a 100% objective response rate and an 83.3% complete response rate. No dose-limiting toxicities, serious adverse events, or immune effector cell-associated neurotoxicity syndrome cases were reported. Infusion-related reactions occurred in nine patients but resolved within a median of two days.

The In Vivo Distinction

The strategic significance of LB2501 lies in its departure from conventional CAR-T manufacturing. Traditional cell therapies require extracting a patient's T-cells, engineering them externally in specialized facilities, and reinfusing the modified product. LB2501 is designed to generate CAR-T cells directly within the patient through a single infusion, removing the ex vivo manufacturing step entirely.

This distinction carries meaningful implications for scalability and patient access. Conventional CAR-T timelines and infrastructure requirements have historically constrained availability, particularly for patients in rapid progression. An effective in vivo platform could widen the addressable population while reducing delivery complexity. Chief Executive Ying Huang noted the approach carries potential to reach patients ineligible for traditional cell therapies due to clinical or logistical barriers.

Pipeline Breadth and Sector Dynamics

The LB2501 data arrived alongside broader disclosures at ASCO 2026. Legend's investigational DLL3-targeting therapy, LB2102, reported first-in-human results in patients with relapsed or refractory small cell lung cancer and large-cell neuroendocrine carcinoma, with an objective response rate of 28.6% and a disease control rate of 78.6% at higher dose levels. Updated CARTITUDE program data for CARVYKTI, the company's approved BCMA-targeting therapy, continued to reinforce durable efficacy in multiple myeloma.

The in vivo CAR-T space has attracted rising deal-making activity. AstraZeneca and Eli Lilly have recently executed transactions in this field, reflecting sector conviction that next-generation cell therapies will migrate toward in vivo platforms. Oppenheimer analyst Kostas Biliouris described the LB2501 data as pointing to a potentially best-in-class profile in the space and noted the results strengthen the case for a potential acquisition of Legend. RBC Capital maintained its Outperform rating with a US$64 price target; consensus analyst estimates place the target at US$75.16.

Conclusion

The LB2501 Phase 1 data offers early validation of an approach that, if sustained through larger trials, could alter the cost structure and accessibility of cell therapy. The in vivo model sidesteps manufacturing bottlenecks that have constrained conventional CAR-T adoption, and a pipeline spanning solid tumors, hematologic malignancies, and a commercialised product gives Legend a multi-front platform narrative with growing credibility. Durability of responses at expanded cohorts and longer follow-up will be the critical test. The June 2 session nonetheless signalled that Capital Markets and sector participants are increasingly aligned on one view: in vivo cell therapy may represent the field's most consequential structural shift in years.